Boston-based pharma company Ratio Therapeutics has initiated dosing in a phase 1 study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical, RTX-1363S, for PET imaging in adult healthy volunteers.
A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers